GUEST COLUMNISTS

• The Promise Of MRD-Guided CAR-T Treatment

  Minimal residual disease markers can reveal relapse before clinical signs appear, when off-the-shelf cell therapy may have its greatest advantage.

• Your Trial Shows Up In AI. Now What?

  AI can explain your trial — but can it help patients act? Ross Jackson shares how sponsors can turn visibility into trust and next steps.

• Dose Escalation, Combination Strategy Keep Aprea Ahead In Its Oncology Trials

  Aprea’s Gene Kennedy explains how smart dose escalation, next-gen sequencing, and combination planning are helping the company advance its oncology trial for multiple solid tumor types.

• How A $96M Gift Is Transforming Pediatric Brain Cancer Clinical Trial Infrastructure

  By pairing donor priorities with research needs at Children's National, Milken Institute SPARC is turning philanthropy into faster trials, stronger infrastructure, and long-term care goals.

• Lessons In Forecasting Discipline From A $40B Supply Chain

  Forecasting errors rarely start with the algorithm. They start when protocol changes, enrollment and site data reach the supply plan too late to prevent waste and disruption.

• The Pharmacy Benefit No One Is Managing: Clinical Research As A Care Option

  Pharmacies could make trials more accessible — if they preserve patient trust while research partners handle the operational burden.

• Planning A Global Clinical Trial With The Right Sites, Not The Most Sites

  Less is more for Yi Larson and the team at Excursion Therapeutics, which opted to build right site network — not the largest one — for its Phase 2 trial.

• Turning Pediatric Cancer Discoveries Into Medicines Requires Better Connections

  Promising pediatric cancer science often stalls before patients benefit. David Adler explains how better connections could change that.